Our model utilizes four immune variables which are significantly associated with clinical outcomes for ESCC, including the infiltration of CD8+/Foxp3+/CD33+ cells and the expression of PD-L1 by tumor cells. This evidence concerns the gene FOXP3 and esophageal squamous cell carcinoma.